Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib Plus Capecitabine in Advanced Biliary Tract Cancer
NCT03231176Phase 2Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of varlitinib in biliary tract cancer (BTC), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Objective Response Rate at 2 years. Started Dec 2017; status: completed.
02
Drugs
varlitinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03231176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231176.